Physician profile
Eric L Martinez
NPI 1952761868
$9,181.99
in general payments reported to CMS, 2019-2025
30 companies · $6,493 in 2025
The $6,493 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $204 · 2022: $554 · 2023: $624 · 2024: $1,308 · 2025: $6,493.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,423 · Consulting Fee: $2,500 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $800 · Travel and Lodging: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,423.27 |
| Consulting Fee | $2,500.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $800.00 |
| Travel and Lodging | $701.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $4,940.53 | 2022-2025 | Caplyta |
| Abbvie INC. | $605.47 | 2021-2025 | |
| Tris Pharma INC | $371.46 | 2024-2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Janssen Pharmaceuticals, INC | $344.63 | 2021-2025 | Spravato, Invega Sustenna |
| Axsome Therapeutics, INC. | $334.73 | 2024-2025 | Auvelity |
| Viiv Healthcare Company | $302.54 | 2022-2025 | Apretude |
| Takeda Pharmaceuticals U.S.A., INC. | $290.23 | 2021-2025 | Trintellix |
| Alkermes, INC. | $274.27 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $257.72 | 2022-2025 | Rexulti |
| Neos Therapeutics, LP | $170.44 | 2024-2025 | Adzenys Xr-Odt |
| E.R. Squibb & Sons, L.L.C. | $164.92 | 2025 | Cobenfy |
| Lundbeck LLC | $128.15 | 2024-2025 | Rexulti |
| Novo Nordisk INC | $102.05 | 2023-2024 | Wegovy, Rybelsus, Ozempic |
| Collegium Pharmaceutical, INC. | $91.21 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $89.54 | 2024-2025 | Loreev Xr |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $89.40 | 2022-2025 | Azstarys |
| Bausch Health US, LLC | $88.58 | 2024-2025 | Wellbutrin, Aplenzin |
| Supernus Pharmaceuticals, INC. | $80.84 | 2024-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $77.97 | 2024 | |
| Gilead Sciences, INC. | $75.43 | 2021 | |
| Neurocrine Biosciences, INC. | $65.23 | 2025 | |
| Vertical Pharmaceuticals, LLC | $40.14 | 2025 | Relexxii |
| Indivior INC. | $34.69 | 2025 | Sublocade |
| Teva Pharmaceuticals USA, INC. | $33.16 | 2024 | Austedo Xr |
| Luye Pharma (USA) LTD. | $29.49 | 2025 | Erzofri Extended-Release |
| Noven Therapeutics, LLC | $22.92 | 2024 | Xelstrym |
| Hologic Sales and Service, LLC | $21.16 | 2023 | Aptima |
| Genentech USA, INC. | $20.56 | 2021 | |
| Pfizer INC. | $17.90 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.63 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.